Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Provectus secures new patent
November 2018
SHARING OPTIONS:

KNOXVILLE, Tenn.—The U.S. Patent and Trademark Office has allowed Provectus’ patent application for the use of adoptive cell transfer of PV-10-induced T cells for treating solid tumor cancers, the company announced recently. Under the patent’s treatment concept, PV-10 is injected into solid tumors, and then T cells trained through PV-10 oncolytic immunotherapy to target treated tumors are harvested, banked and amplified. These amplified T cells can then be administered via adoptive cell transfer. The patent covers such treatment for either the original patient or other immunologically suitable patients. PV-10, an investigational drug for treating adult/pediatric solid tumor cancers, is the first small-molecule oncolytic immunotherapy. PV-10 is administered through intralesional injection into superficial or visceral tumors to trigger immunogenic cell death, and is being evaluated in multiple cancer types.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.